ir.syntapharma.com ir.syntapharma.com

ir.syntapharma.com

Synta Pharmaceuticals Corp : Investors : Investor Overview

Trials by Tumor Type. Synta Pharmaceuticals is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. . 160;- 0.01. Aug 07, 2015 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. Synta Reports Second Quarter 2015 Financial Results. Aug 06, 2015. Synta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015.

http://ir.syntapharma.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR IR.SYNTAPHARMA.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

August

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 3.8 out of 5 with 10 reviews
5 star
5
4 star
2
3 star
1
2 star
0
1 star
2

Hey there! Start your review of ir.syntapharma.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

CONTACTS AT IR.SYNTAPHARMA.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Synta Pharmaceuticals Corp : Investors : Investor Overview | ir.syntapharma.com Reviews
<META>
DESCRIPTION
Trials by Tumor Type. Synta Pharmaceuticals is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. . 160;- 0.01. Aug 07, 2015 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. Synta Reports Second Quarter 2015 Financial Results. Aug 06, 2015. Synta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015.
<META>
KEYWORDS
1 about us
2 company overview
3 management team
4 board of directors
5 directions
6 pipeline
7 overview
8 ganetespib
9 presentations
10 publications
CONTENT
Page content here
KEYWORDS ON
PAGE
about us,company overview,management team,board of directors,directions,pipeline,overview,ganetespib,presentations,publications,elesclomol,clinical trials,non small cell lung cancer,breast cancer,colon/rectal cancer,ovarian cancer,mesothelioma,galaxy
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Synta Pharmaceuticals Corp : Investors : Investor Overview | ir.syntapharma.com Reviews

https://ir.syntapharma.com

Trials by Tumor Type. Synta Pharmaceuticals is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. . 160;- 0.01. Aug 07, 2015 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. Synta Reports Second Quarter 2015 Financial Results. Aug 06, 2015. Synta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015.

OTHER SITES

ir.syahrasi.com ir.syahrasi.com

Iramasuka Tours & Travel

Deprecated: Function set magic quotes runtime() is deprecated in /home/adjie/public html/iramasuka/textpattern/lib/txplib db.php on line 14. Iramasuka Tours and Travel. It is a great pleasure for us to provide you our reliable Sulawesi tour programs which more rich of wonderful unique cultures and natural beauties. And wonderful seatrek of TOGIAN. Should you require more information about our products, iramasuka will be your best choice. Round The South Sulawesi. Round The South East Sulawesi.

ir.sycamorenet.com ir.sycamorenet.com

SYCAMORENET.COM

ir.synageva.com ir.synageva.com

Synageva :: Investor Relations

Effective June 23, 2015 Synageva BioPharma Corp. is now part of Alexion Pharmaceuticals, Inc. You will be redirected in 10 seconds. Our Mission / Commitment. What is a Rare Disease? Section 16 Filings (3,4,5). Synageva BioPharma Corp. (NASDAQ: GEVA). Synageva is a biopharmaceutical company dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. We are passionate about our commitment to improving the lives of patients for generations ...

ir.syndax.com ir.syndax.com

Investors – Syndax

Annual Reports and Proxies. Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA. Day High: 7.40.

ir.synnex.com ir.synnex.com

Investor Relations | SYNNEX Corporation

Skip to main navigation. Technology Solutions Executive Team. New Age Electronics (U.S.). SYNNEX Completes Acquisition of Westcon-Comstor North America and Latin America Businesses. Annual Reports and Proxies. Mar 29, 2018. SYNNEX Corporation Reports First Quarter Fiscal 2018 Results. Mar 20, 2018. SYNNEX Corporation Launches Exclusive IT Reseller Community Focused on Technology Convergence. Sign up for email alerts. Mar 29, 2018 5:00 PM EDT. Q1 2018 SYNNEX Corporation Earnings Conference Call.

ir.syntapharma.com ir.syntapharma.com

Synta Pharmaceuticals Corp : Investors : Investor Overview

Trials by Tumor Type. Synta Pharmaceuticals is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. . 160;- 0.01. Aug 07, 2015 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. Synta Reports Second Quarter 2015 Financial Results. Aug 06, 2015. Synta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015.

ir.synthesisenergy.com ir.synthesisenergy.com

Investor Center | Synthesis Energy Systems, Inc.

Skip to main navigation. How Syngas is Used. Why Syngas is Important. Global Need and Resources. The Future of Gasification. The Real Cost of Energy. SGT: How It Works. How Syngas is Used. Why Syngas is Important. Global Need and Resources. The Future of Gasification. The Real Cost of Energy. SGT: How It Works. DRI for Steel Production. Clean Economic. Sustainable. Growth With Blue Skies. Synthesis Energy Systems, Inc. 30th Annual ROTH Conference 2018 Presentation. Mar 26, 2018. Mar 12, 2018. Mar 5, 2018.

ir.syntheticbiologics.com ir.syntheticbiologics.com

Investor Relations :: Synthetic Biologics, Inc. (SYN)

Jan 5, 2017. Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI). Sep 30, 2016. Sign Up for Email Alerts Sign Up Today. Our experienced management team holds an extensive clinical and commercial track record. View Board of Directors. Synthetic Biologics, Inc. Corporate Stock Transfer, Inc. 3200 Cherry Creek Drive South. Denver, CO 80209.

ir.synu.edu.cn ir.synu.edu.cn

沈阳师范大学机构知识库: Home

CALIS Institutional Repository (CALIS IR) is the academic research infrastructure of school. It's a central, open-access repository of research by members of the Peking University. Research Field : 古生物学、地层学,专长于中生代植物及早期被子植物研究。 Research Field : 从事现、当代文学和前沿文化、文学研究。 Research Field : 两栖爬行动物资源和保护生物学研究工作. New in CALIS IR. Institutional Repository Project Group, Powered by DSpace Feedback. Number of Online Users: 212 Total of Site Visit: 3297032.

ir.sypris.com ir.sypris.com

Sypris Solutions Inc. (SYPR) - Investor Information

Q2 2015 Sypris Solutions Inc. Earnings Conference Call. 160;at 9:00 am ET. Q2 2015 Sypris Solutions Inc. Earnings Conference Call. Tuesday, August 18, 2015 . 9:00 am ET  . Click here for webcast. Sypris Solutions, Inc. Louisville, KY 40222. 160; 0.09. Data as of 08/17/15 4:00 pm ET. Minimum 20 minute delay. Sypris Solutions, Inc. to Announce Second Quarter Financial Results, Host Conference Call and Webcast on August 18. Sypris Reports First Quarter Results. Sypris Reports 2014 Results. Industrial Margin...

ir.syzygy.co.uk ir.syzygy.co.uk

www.syzygy.net

WELCOME AT SYZYGY AG! SYZYGY AG is an award-winning agency group for digital marketing, listed since the year 2000. Employing some 500 people, the Group provides creative, media and technology services. Offices are based in Bad Homburg, Berlin, Hamburg, Frankfurt, Munich, London, New York and Warsaw. SYZYGY`s client list includes renowned brands such as Avis, BMW, Chanel, Daimler, Discovery Channel, Jägermeister, Mazda, nvidia, o2, playstation and Telekom. In 2014, SYZYGY Group continued to grow dynamica...